Savvy Updates 5/1/23:  Lilly Sells Off Baqsimi, Humacyte Biovascular Pancreas, Dexcom Growth, Know Labs Non-Invasive Sensor, Medtronic Resolves FDA Warning Letter, Omnipod GO for T2D, Doctors More Neurotic, Diabetes Standards of Care, 2023

Savvy Updates 5/1/23: Lilly Sells Off Baqsimi, Humacyte Biovascular Pancreas, Dexcom Growth, Know Labs Non-Invasive Sensor, Medtronic Resolves FDA Warning Letter, Omnipod GO for T2D, Doctors More Neurotic, Diabetes Standards of Care, 2023

Lilly sells emergency diabetes drug for $500M by Jonathan Gardner for BioPharmaDive.com, 24 April 2023. Eli Lilly will sell its emergency diabetes treatment Baqsimi to Amphastar Pharmaceuticals for $500 million upfront, the company said, divesting a drug launched...
Savvy Updates 4/24/23: Abbott Libre 3 Reader Cleared, Medtronic MiniMed 780G System Cleared by FDA, Diamyd Precision Medicine Antigen-Specific Immunotherapy, Aspect Biosystems/3D bioprinting, Blackstone Using AI to Control Diabetes, What is Deja Vu?

Savvy Updates 4/24/23: Abbott Libre 3 Reader Cleared, Medtronic MiniMed 780G System Cleared by FDA, Diamyd Precision Medicine Antigen-Specific Immunotherapy, Aspect Biosystems/3D bioprinting, Blackstone Using AI to Control Diabetes, What is Deja Vu?

Abbott gets clearance for Libre 3 reader, opening path to Medicare coverage by Elise Reuter for MedTechDive.com, 17 April 2023.   Since Medicare covers CGMs as durable medical equipment, the devices must include a component, such as a reader, that is...
Savvy Updates 4/17/23: ChatGPT as Diabetes Educator, Undbio Korean Insulin Comes to W. VA, 8000 Brisk Steps/Day, Blueberries, GoBag/DayPack, Who’s in Control in the Hospital?

Savvy Updates 4/17/23: ChatGPT as Diabetes Educator, Undbio Korean Insulin Comes to W. VA, 8000 Brisk Steps/Day, Blueberries, GoBag/DayPack, Who’s in Control in the Hospital?

Can ChatGPT Replace Diabetes Educators? Perhaps Not Yet by Liam Davenport for MedScape.com, 14 April 2023.   ChatGPT, the novel artificial intelligence (AI) tool that has attracted interest and controversy in seemingly equal measure, can provide clear and...
Skip to content